Gastric and oesophageal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 84
• PD-1 108
• PD-L1 49
• CLDN18 35
• TP53 1
• PI3K 1
• AKT 1
• STAT3 1
• mTOR 0
• CTNNB1 0
• VEGF 7
• YAP 0
• MAPK 0
• EGFR 10
• ERK 0
• FGFR 1
• JAK 0
• HIF-1 0
• MYC 0
• PTEN 3
• CTLA-4 8
• NRF2 0
• MET 5
• STING 0
• CXCR4 0
• B7-H3 6
• JNK 0
• AMPK 0
• GPX4 0
• TROP2 6
• IL-6 0
• METTL3 0
• COX-2 0
• KRAS 2
• ARID1A 1
• BRCA1 2
• FAK 0
• LAG-3 0
• MDM2 0
• MMP-9 0
• PARP 0
• PPAR 0
• TIGIT 1
• BRCA2 1
• HSP90 0
• BCL-2 0
• FTO 0
• SHP2 0
• BRAF 0
• CD47 1
• CDK4/6 0
• HDAC 0
• HER3 3
• HMGB1 1
• MEK 0
• PDGFR 2
• TIM-3 0
• TNF 0
• ATM 0
• AXL 2

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Trials whose registry record says individual participant data (IPD) will be shared.

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 71
• Organoids 34
• Mendelian Randomization Analysis 42
• CRISPR-Cas Systems 9
• Gene Expression Profiling 197
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 8
• Exome Sequencing 14
• Proteomics 54
• Metabolomics 42
• Mass Spectrometry 5
• Flow Cytometry 33
• Immunohistochemistry 151
• Liquid Biopsy 18
• Circulating Tumor DNA 25
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 22
• Magnetic Resonance Imaging 23
• Machine Learning 133
• Deep Learning 65
• Cohort Studies 175
• Genome-Wide Association Study 48

• A comprehensive gene expression analysis of gastric cancer cell lines: application of prognostic genes for gene set enrichment analysis to identify poor prognosis-associated signatures.

  Hum Cell, Nov 2026

• High-resolution Spatial Transcriptomics Reveals Contrasting Tumor States in Two Early Gastric Cancers.

  Anticancer Res, Nov 2026

• Gene Expression Profiling and Clinical Validation Reveal CEBPB for Early Diagnosis of Esophageal Squamous Cell Carcinoma.

  Cancer Rep (Hoboken), Nov 2026

• Integrative Multiomics Mendelian Randomization Prioritizes Endoplasmic Reticulum Stress-Related Genes Associated With Gastric Cancer Risk.

  Hum Mutat, Oct 2026

• Integrated in silico and in vitro analysis identifies a co-expression pattern associated with cisplatin/5-FU treatment response and metastatic features in gastric cancer.

  Mol Biol Rep, Oct 2026

• Identification of heterogeneous subtypes of human dendritic cells from the lymph nodes of patients with gastric cancer.

  Front Immunol, Oct 2026

• MTHFD1L-associated branched-chain amino acid degradation transcriptional signature represents a conserved metabolic program in Epstein-Barr virus-associated malignancies.

  Front Cell Infect Microbiol, Oct 2026

• Spatial Transcriptomic Profiling of FAP-Positive Cells in Gastric Cancer and Association with Immunotherapy Efficacy.

  Asian Pac J Cancer Prev, Oct 2026

• Prognostic and immunotherapeutic efficacy predictive model for gastric cancer based on ferroptosis- and autophagy-related genes.

  J Cancer Res Ther, Sept 2026

• A palmitoylation-associated three-gene signature predicts prognosis, immune features, and drug sensitivity in gastric cancer: functional validation of CTHRC1.

  Front Immunol, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.